These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7116703)

  • 1. Impaired lymphocyte transformation in minimal change nephropathy in remission.
    Chapman S; Taube D; Brown Z; Williams DG
    Clin Nephrol; 1982 Jul; 18(1):34-8. PubMed ID: 7116703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression of normal lymphocyte transformation by sera of patients with minimal change nephropathy and other forms of nephrotic syndrome.
    Taube D; Chapman S; Brown Z; Williams DG
    Clin Nephrol; 1981 Jun; 15(6):286-90. PubMed ID: 7249426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired lymphocyte and suppressor cell function in minimal change nephropathy, membranous nephropathy and focal glomerulosclerosis.
    Taube D; Brown Z; Williams DG
    Clin Nephrol; 1984 Oct; 22(4):176-82. PubMed ID: 6239722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory factors of lymphocyte transformation in sera from patients with minimal change nephrotic syndrome.
    Beale MG; Hoffsten PE; Robson AM; MacDermott RP
    Clin Nephrol; 1980 Jun; 13(6):271-6. PubMed ID: 6447569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced beta 2-microglobulin levels in lymphocyte culture supernatants from patients with idiopathic nephrotic syndrome: inhibition of lymphocyte activation by cyclosporine.
    Robeva R; Heslan JM; Branellec A; Laurent J; Lagrue G
    Clin Nephrol; 1988 Oct; 30(4):211-5. PubMed ID: 3063418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell mediated immunity in idiopathic glomerulonephritis.
    Sasdelli M; Cagnoli L; Candi P; Mandreoli M; Beltrandi E; Zucchelli P
    Clin Exp Immunol; 1981 Oct; 46(1):27-34. PubMed ID: 6978215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome.
    Kyrieleis HA; Levtchenko EN; Wetzels JF
    Am J Kidney Dis; 2007 May; 49(5):592-7. PubMed ID: 17472840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of mesangial IgM deposition in "minimal change" nephrotic syndrome.
    Vilches AR; Turner DR; Cameron JS; Ogg CS; Chantler C; Williams DG
    Lab Invest; 1982 Jan; 46(1):10-5. PubMed ID: 7054586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
    Jha V; Ganguli A; Saha TK; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V
    J Am Soc Nephrol; 2007 Jun; 18(6):1899-904. PubMed ID: 17494881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of steroids, cyclosporin and cyclophos-phamide in steroid resistant idiopathic nephrotic syndrome.
    Hafeez F; Ahmad TM; Anwar S
    J Coll Physicians Surg Pak; 2005 Jun; 15(6):329-32. PubMed ID: 15924835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome.
    Ueda N; Takahashi K; Akioka Y; Morooka M; Ogawa A; Tsuzuki K
    J Nephrol; 2009; 22(5):610-5. PubMed ID: 19809993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy.
    Feehally J; Beattie TJ; Brenchley PE; Coupes BM; Houston IB; Mallick NP; Postlethwaite RJ
    N Engl J Med; 1984 Feb; 310(7):415-20. PubMed ID: 6229699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difficult-to-treat nephrotic syndrome: management and outcome.
    Sumboonnanonda A; Chongchate N; Suntornpoch V; Pattaragarn A; Supavekin S
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S142-8. PubMed ID: 16856434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term impairment of suppressor-cell function by cyclophosphamide in minimal-change nephropathy and its association with therapeutic response.
    Taube D; Brown Z; Williams DG
    Lancet; 1981 Jan; 1(8214):235-8. PubMed ID: 6109898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary observation on lymphocyte function with radioisotope incorporation in asthmatic patients].
    Wang GJ
    Zhonghua Jie He He Hu Xi Za Zhi; 1991 Feb; 14(1):17-8, 61. PubMed ID: 1879004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history and response to treatment of minimal change nephrotic syndrome.
    Prabhakar KS; Prakash KC; Mani MK
    J Assoc Physicians India; 1993 May; 41(5):263-5. PubMed ID: 8300454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
    Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
    Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone.
    Eriguchi M; Oka H; Mizobuchi T; Kamimura T; Sugawara K; Harada A
    Nephrol Dial Transplant; 2009 Oct; 24(10):3082-8. PubMed ID: 19465558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW; Fluck RJ; Lambie SH
    Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children.
    Gulati S; Prasad N; Sharma RK; Kumar A; Gupta A; Baburaj VP
    Nephrol Dial Transplant; 2008 Mar; 23(3):910-3. PubMed ID: 18039644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.